Akero Therapeutics Inc (NAS:AKRO)
$ 20.295 0.155 (0.77%) Market Cap: 1.40 Bil Enterprise Value: 525.23 Mil PE Ratio: 0 PB Ratio: 1.66 GF Score: 41/100

Akero Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:45PM GMT
Release Date Price: $24.13 (+5.65%)
Eric Joseph JPMorgan Chase;Co.;Moderator

&-

All right, so we'll get started here. I'm [Eric Joseph], Senior Biotech Analyst at JPMorgan. Our next presenting company is Akero Therapeutics, and with us to bring us through the story is CEO Andrew Cheng. There is going to be a Q&A session after the presentation. Just raise your hand and we'll bring a mic around. And for folks tuning in via the webcast, feel free to submit questions by clicking the ask-a-question button. With that, Andrew?

Andrew Cheng
Akero Therapeutics Inc - President, Chief Executive Officer, Director

Thank you very much for having us, and we're excited to be back and really to be moving into '24. I think that '23 is an eventful year for us, and it really set us up well for how we're going to be moving forward. So I have to show my Safe Harbor slide to please my legal counsel, but I think that's enough. And so when you think about where we are as a company, we're a clinical-stage Phase 3 company, and that's really exemplified by our press release at the end of last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot